Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 313 to 318 of 318 entries
Sorted by: Best Match Show Resources per page
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer.

Investigational new drugs

Maurice-Dror C, Le Moigne R, Vaishampayan U, Montgomery RB, Gordon MS, Hong NH, DiMascio L, Perabo F, Chi KN.
PMID: 34843005
Invest New Drugs. 2021 Nov 29; doi: 10.1007/s10637-021-01202-6. Epub 2021 Nov 29.

BACKGROUND: EPI-506 is the first of a new class of drugs targeting the N-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming known resistance mechanisms to androgen receptor pathway inhibitors (ARPIs) among men with metastatic castration resistant prostate...

Cite
Maurice-Dror C, Le Moigne R, Vaishampayan U, et al. A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer. Invest New Drugs. 2021;doi: 10.1007/s10637-021-01202-6.
Maurice-Dror, C., Le Moigne, R., Vaishampayan, U., Montgomery, R. B., Gordon, M. S., Hong, N. H., DiMascio, L., Perabo, F., & Chi, K. N. (2021). A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer. Investigational new drugs, . https://doi.org/10.1007/s10637-021-01202-6
Maurice-Dror, Corinne, et al. "A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer." Investigational new drugs vol. (2021). doi: https://doi.org/10.1007/s10637-021-01202-6
Maurice-Dror C, Le Moigne R, Vaishampayan U, Montgomery RB, Gordon MS, Hong NH, DiMascio L, Perabo F, Chi KN. A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer. Invest New Drugs. 2021 Nov 29; doi: 10.1007/s10637-021-01202-6. Epub 2021 Nov 29. PMID: 34843005.
Copy Download .nbib Format: NLM
Successful treatment of a case of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen.

Investigational new drugs

Isomoto K, Haratani K, Watanabe S, Takeda M, Iwasa T, Nakagawa K.
PMID: 34463889
Invest New Drugs. 2022 Feb;40(1):194-197. doi: 10.1007/s10637-021-01168-5. Epub 2021 Aug 31.

Extramammary Paget disease (EMPD) is a rare cutaneous adenocarcinoma that usually is of epidermal origin and shows glandular differentiation and that is treated by wide local excision depending on the disease extent. For widely metastatic disease, however, a standard...

Cite
Isomoto K, Haratani K, Watanabe S, et al. Successful treatment of a case of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen. Invest New Drugs. 2021;40(1):194-197doi: 10.1007/s10637-021-01168-5.
Isomoto, K., Haratani, K., Watanabe, S., Takeda, M., Iwasa, T., & Nakagawa, K. (2022). Successful treatment of a case of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen. Investigational new drugs, 40(1), 194-197. https://doi.org/10.1007/s10637-021-01168-5
Isomoto, Kohsuke, et al. "Successful treatment of a case of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen." Investigational new drugs vol. 40,1 (2022): 194-197. doi: https://doi.org/10.1007/s10637-021-01168-5
Isomoto K, Haratani K, Watanabe S, Takeda M, Iwasa T, Nakagawa K. Successful treatment of a case of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen. Invest New Drugs. 2022 Feb;40(1):194-197. doi: 10.1007/s10637-021-01168-5. Epub 2021 Aug 31. PMID: 34463889.
Copy Download .nbib Format: NLM
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.

Investigational new drugs

Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA.
PMID: 34515877
Invest New Drugs. 2022 Feb;40(1):115-123. doi: 10.1007/s10637-021-01175-6. Epub 2021 Sep 13.

PURPOSE: Targeting the vascular endothelial growth factor (VEGF) pathway improves progression free survival in multiple advanced malignancies but durable responses are uncommon. Inhibition of the VEGF pathway at multiple levels of signal transduction may improve clinical outcomes. Preclinical data...

Cite
Hubbard JM, Yin J, Schenk EL, et al. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2021;40(1):115-123doi: 10.1007/s10637-021-01175-6.
Hubbard, J. M., Yin, J., Schenk, E. L., Qin, R., Reid, J. M., Strand, C., Fiskum, J., Menefee, M., Lin, G., Doyle, L. A., Ivy, P., Erlichman, C., Adjei, A., Haluska, P., & Costello, B. A. (2022). Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Investigational new drugs, 40(1), 115-123. https://doi.org/10.1007/s10637-021-01175-6
Hubbard, Joleen M, et al. "Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies." Investigational new drugs vol. 40,1 (2022): 115-123. doi: https://doi.org/10.1007/s10637-021-01175-6
Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2022 Feb;40(1):115-123. doi: 10.1007/s10637-021-01175-6. Epub 2021 Sep 13. PMID: 34515877.
Copy Download .nbib Format: NLM
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.

Investigational new drugs

Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T.
PMID: 34495421
Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08.

Few clinical studies have been designed for elderly patients with locally advanced non-small cell lung cancer (NSCLC). We conducted a phase I study to evaluate the tolerability of carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy in elderly patients with locally advanced...

Cite
Omori S, Harada H, Mori K, et al. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2021;40(1):106-114doi: 10.1007/s10637-021-01155-w.
Omori, S., Harada, H., Mori, K., Hisamatsu, Y., Tsuboguchi, Y., Yoshioka, H., Morinaga, R., Daga, H., Kurata, T., & Takahashi, T. (2022). Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Investigational new drugs, 40(1), 106-114. https://doi.org/10.1007/s10637-021-01155-w
Omori, Shota, et al. "Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer." Investigational new drugs vol. 40,1 (2022): 106-114. doi: https://doi.org/10.1007/s10637-021-01155-w
Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08. PMID: 34495421.
Copy Download .nbib Format: NLM
KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.

Investigational new drugs

Zhou X, Wang N, Zhang Y, Yu H, Wu Q.
PMID: 34499335
Invest New Drugs. 2022 Feb;40(1):43-57. doi: 10.1007/s10637-021-01159-6. Epub 2021 Sep 09.

BACKGROUND: Over the past few years, dramatic breakthroughs in the field of tumor immunotherapy with immune checkpoint inhibitors (ICIs) have made a therapeutic revolution for non-small cell lung cancer (NSCLC). While only some patients present a favorable response to...

Cite
Zhou X, Wang N, Zhang Y, et al. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer. Invest New Drugs. 2021;40(1):43-57doi: 10.1007/s10637-021-01159-6.
Zhou, X., Wang, N., Zhang, Y., Yu, H., & Wu, Q. (2022). KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer. Investigational new drugs, 40(1), 43-57. https://doi.org/10.1007/s10637-021-01159-6
Zhou, Xue, et al. "KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer." Investigational new drugs vol. 40,1 (2022): 43-57. doi: https://doi.org/10.1007/s10637-021-01159-6
Zhou X, Wang N, Zhang Y, Yu H, Wu Q. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer. Invest New Drugs. 2022 Feb;40(1):43-57. doi: 10.1007/s10637-021-01159-6. Epub 2021 Sep 09. PMID: 34499335.
Copy Download .nbib Format: NLM
Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.

Investigational new drugs

Modi T, Gervais D.
PMID: 34468906
Invest New Drugs. 2022 Feb;40(1):21-29. doi: 10.1007/s10637-021-01173-8. Epub 2021 Sep 01.

INTRODUCTION:  Erwinase® (native Erwinia chrysanthemi L-Asparaginase (nErA)) is an approved second-line treatment for acute lymphoblastic leukaemia (ALL) in children and adolescents, who develop hypersensitivity or neutralising antibodies to E.coli derived L-Asparaginases (ASNases). However, nErA has a short in vivo...

Cite
Modi T, Gervais D. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Invest New Drugs. 2021;40(1):21-29doi: 10.1007/s10637-021-01173-8.
Modi, T., & Gervais, D. (2022). Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Investigational new drugs, 40(1), 21-29. https://doi.org/10.1007/s10637-021-01173-8
Modi, Tapasvi, and Gervais, David. "Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase." Investigational new drugs vol. 40,1 (2022): 21-29. doi: https://doi.org/10.1007/s10637-021-01173-8
Modi T, Gervais D. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Invest New Drugs. 2022 Feb;40(1):21-29. doi: 10.1007/s10637-021-01173-8. Epub 2021 Sep 01. PMID: 34468906.
Copy Download .nbib Format: NLM
Showing 313 to 318 of 318 entries